Literature DB >> 30498719

Increased mutant KRAS gene dosage drives pancreatic cancer progression: evidence for wild-type KRAS as a tumor suppressor?

Oliver A Kent1.   

Abstract

Entities:  

Year:  2018        PMID: 30498719      PMCID: PMC6230847          DOI: 10.21037/hbsn.2018.07.03

Source DB:  PubMed          Journal:  Hepatobiliary Surg Nutr        ISSN: 2304-3881            Impact factor:   7.293


× No keyword cloud information.
  9 in total

1.  Cancer statistics, 2018.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-01-04       Impact factor: 508.702

Review 2.  ras genes.

Authors:  M Barbacid
Journal:  Annu Rev Biochem       Date:  1987       Impact factor: 23.643

3.  GTP-Dependent K-Ras Dimerization.

Authors:  Serena Muratcioglu; Tanmay S Chavan; Benjamin C Freed; Hyunbum Jang; Lyuba Khavrutskii; R Natasha Freed; Marzena A Dyba; Karen Stefanisko; Sergey G Tarasov; Attila Gursoy; Ozlem Keskin; Nadya I Tarasova; Vadim Gaponenko; Ruth Nussinov
Journal:  Structure       Date:  2015-06-04       Impact factor: 5.006

4.  Ras in cancer and developmental diseases.

Authors:  Alberto Fernández-Medarde; Eugenio Santos
Journal:  Genes Cancer       Date:  2011-03

Review 5.  Pancreatic cancer.

Authors:  Anirban Maitra; Ralph H Hruban
Journal:  Annu Rev Pathol       Date:  2008       Impact factor: 23.472

Review 6.  The role of wild type RAS isoforms in cancer.

Authors:  Bingying Zhou; Channing J Der; Adrienne D Cox
Journal:  Semin Cell Dev Biol       Date:  2016-07-13       Impact factor: 7.727

7.  KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS.

Authors:  Chiara Ambrogio; Jens Köhler; Zhi-Wei Zhou; Haiyun Wang; Raymond Paranal; Jiaqi Li; Marzia Capelletti; Cristina Caffarra; Shuai Li; Qi Lv; Sudershan Gondi; John C Hunter; Jia Lu; Roberto Chiarle; David Santamaría; Kenneth D Westover; Pasi A Jänne
Journal:  Cell       Date:  2018-01-11       Impact factor: 41.582

8.  Disruption of p16 and activation of Kras in pancreas increase ductal adenocarcinoma formation and metastasis in vivo.

Authors:  Wanglong Qiu; Fikret Sahin; Christine A Iacobuzio-Donahue; Dario Garcia-Carracedo; Wendy M Wang; Chia-Yu Kuo; Doris Chen; Dan E Arking; Andrew M Lowy; Ralph H Hruban; Helen E Remotti; Gloria H Su
Journal:  Oncotarget       Date:  2011-11

9.  Evolutionary routes and KRAS dosage define pancreatic cancer phenotypes.

Authors:  Sebastian Mueller; Thomas Engleitner; Roman Maresch; Magdalena Zukowska; Sebastian Lange; Thorsten Kaltenbacher; Björn Konukiewitz; Rupert Öllinger; Maximilian Zwiebel; Alex Strong; Hsi-Yu Yen; Ruby Banerjee; Sandra Louzada; Beiyuan Fu; Barbara Seidler; Juliana Götzfried; Kathleen Schuck; Zonera Hassan; Andreas Arbeiter; Nina Schönhuber; Sabine Klein; Christian Veltkamp; Mathias Friedrich; Lena Rad; Maxim Barenboim; Christoph Ziegenhain; Julia Hess; Oliver M Dovey; Stefan Eser; Swati Parekh; Fernando Constantino-Casas; Jorge de la Rosa; Marta I Sierra; Mario Fraga; Julia Mayerle; Günter Klöppel; Juan Cadiñanos; Pentao Liu; George Vassiliou; Wilko Weichert; Katja Steiger; Wolfgang Enard; Roland M Schmid; Fengtang Yang; Kristian Unger; Günter Schneider; Ignacio Varela; Allan Bradley; Dieter Saur; Roland Rad
Journal:  Nature       Date:  2018-01-24       Impact factor: 49.962

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.